# A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina

Study · id `cardio:ct-nct02087007` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02087007](<https://clinicaltrials.gov/study/NCT02087007>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT02087007

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT02087007. Randomized; double masking; primary purpose treatment. Start 2013-11 (registry gives no type); primary completion 2015-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT02087007, source copy `cardio:ctgov-nct02087007-2017-05-04`, retrieved 2026-11-18)
- Start date: 2013-11 (registry gives no type) (ClinicalTrials.gov record NCT02087007, source copy `cardio:ctgov-nct02087007-2017-05-04`, retrieved 2026-11-18)
- Primary completion: 2015-07 (actual) (ClinicalTrials.gov record NCT02087007, source copy `cardio:ctgov-nct02087007-2017-05-04`, retrieved 2026-11-18)
- Completion: 2015-07 (actual) (ClinicalTrials.gov record NCT02087007, source copy `cardio:ctgov-nct02087007-2017-05-04`, retrieved 2026-11-18)
- Countries: South Korea (ClinicalTrials.gov record NCT02087007, source copy `cardio:ctgov-nct02087007-2017-05-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02087007-2017-05-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina
- Acronym: STELLA
- Condition: Vasospastic Angina
- Intervention (Drug): Cilostazol
- Intervention (Drug): placebo
- Lead sponsor: Korea Otsuka Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Microvascular and vasospastic angina (`cardio:microvascular-and-vasospastic-angina`)
- Registry lists this organization as the lead sponsor: Korea Otsuka Pharmaceutical Co., Ltd. (`cardio:org-korea-otsuka-pharmaceutical-co-ltd`)

## Provenance

Content hash: a63437e0ab64a74fab64c27e33f925d968662ead4831852fe501cc496a05eef7
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
